Get started
Author

L. Mary Smith

Observed names: L. M. Smith, L.M. Smith, Laura Smith
OpenAlex ID: A5013467643
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma
2024 · Christopher L. Moertel, Angela C. Hirbe, et al. · Journal of Clinical Oncology · 110
PDF
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
2018 · M. Fevzi Ozkaynak, Andrew L. Gilman, et al. · Frontiers in Immunology · 89
PDF
Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma
2014 · Ami V. Desai, Elizabeth Fox, et al. · Cancer Chemotherapy and Pharmacology · 43
Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.
2022 · Sagar Lonial, Sebastian Grosicki, et al. · Journal of Clinical Oncology · 24
Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy
2016 · Araz Marachelian, Ami Desai, et al. · Cancer Chemotherapy and Pharmacology · 23
PDF
Neuroblastoma in an adult: case presentation and literature review.
2013 · Laura Smith, Steve Minter, et al. · PubMed · 17
ReNeu: A pivotal phase 2b trial of mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform neurofibroma (PN).
2024 · Christopher L. Moertel, Angela C. Hirbe, et al. · Journal of Clinical Oncology · 13
PDF
LBA2 DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT)
2022 · B. Kasper, R. Ratan, et al. · Annals of Oncology · 11
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
2018 · M. Fevzi Ozkaynak, Andrew L. Gilman, et al. · Frontiers in Immunology · 5
PDF
Population pharmacokinetic-pharmacodynamic model of nirogacestat effects on B-cell maturation antigen in healthy subjects.
2023 · Todd Shearer, Rex L. Williams, et al. · Journal of Clinical Oncology · 4
Pharmacodynamic Effects of Nirogacestat, a Gamma Secretase Inhibitor, on B-Cell Maturation Antigen in Healthy Participants
2022 · Todd Shearer, Rex L. Williams, et al. · Blood · 2
P-212: DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM)
2021 · Paul G. Richardson, Suzanne Trudel, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
ReNeu: A Pivotal Phase 2b Trial of Mirdametinib in Children and Adults With Neurofibromatosis Type 1 (NF1)-Associated Symptomatic Plexiform Neurofibroma (PN) (S29.003)
2025 · Hans Shuhaiber, Christopher Moertel, et al. · Neurology
P939: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination With a Gamma-secretase Inhibitor (nirogacestat) in Patients With Relapsed/refractory Multiple Myeloma (rrmm): Dreamm-5 Study
2022 · A. Nooka, S. Lonial, et al. · HemaSphere
Abstract 5775: Survey to identify current physician preferences for the treatment of patients with desmoid tumors
2020 · Jessica White, Badreddin Edris, et al. · Cancer Research
Pharmacokinetics (PK) of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.
2012 · Ami Vijay Desai, Elizabeth Fox, et al. · Journal of Clinical Oncology
Works count: 16
Citation count: 342
H-index: 8
I10-index: 8
Year
Topic
Type